Abstract
The Coronavirus (COVID-19) epidemic, which was first reported in December 2019 in Wuhan, China, has caused 219,331 confirmed cases as of 20 March 2020, with 81,301 cases being reported in China. It has been declared a pandemic by the World Health Organization in 11 March 2020 (1). Although massive intervention measures have been implemented in China (e.g. shutting down cities, extending holidays and travel ban) and many other countries, the spread of the disease are unlikely to be stopped over the world shortly. It is becoming evident that environmental factors are associated with seasonality of respiratory-borne diseases’ epidemics (2). Previous studies have suggested that ambient nitrogen dioxide (NO2) exposure may play a role in the phenotypes of respiratory diseases, including, but not limited to, influenza, asthma and severe acute respiratory syndrome (SARS). NO2), for example, might increase the susceptibility of adults to virus infections (3). High exposure to NO2 before the start of a respiratory viral infection is associated with the severity of asthma exacerbation (4). This study aims to assess the associations of ambient NO2 levels with spread ability of COVID-19 across 63 Chinese cities, and provides information for the further prevention and control of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was sponsored by the Bill & Melinda Gates Foundation (Grant No. OPP1216424) and Fudan University Research Project on COVID-19 Emergency (Grant No. IDF201007).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
COVID-19 confirmed cases and deaths information be obtained from the following link(The first and second link);Daily PM2.5 and PM10 data were obtained from the National Urban Air Quality Publishing Platform(The third link);
http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml
